Literature DB >> 6872940

The effect of a 5 alpha-reductase inhibitor on androgen-mediated growth of the dog prostate.

U K Wenderoth, F W George, J D Wilson.   

Abstract

The administration of testosterone cypionate (0.4 mg/kg BW . day) to castrated male dogs caused a doubling of prostate weight within 4 weeks and an increase in the content of testosterone and dihydrotestosterone in the prostate. When the 5 alpha-reductase inhibitor 17-N,N-diethylcarbamoyl-4-methyl-4-aza-5 alpha-androstan-3-one (3 mg/kg BW . day) was administered simultaneously with testosterone cypionate, prostatic testosterone content increased from 0.5 +/- 0.2 to 4.1 +/- 1.3 ng/mg DNA, the increase in prostatic dihydrotestosterone content was prevented, and prostatic size decreased to half the starting weight. These results suggest that dihydrotestosterone formation plays a role in prostatic growth.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6872940     DOI: 10.1210/endo-113-2-569

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

1.  Molecular Basis of Steroid Action in the Prostate.

Authors:  Yuan-Shan Zhu
Journal:  Cellscience       Date:  2005-04-28

Review 2.  Benign prostatic hyperplasia: the best treatment.

Authors:  G D Chisholm
Journal:  BMJ       Date:  1989-07-22

3.  In vitro study of rat prostate 5 alpha-reductase activity and its inhibition.

Authors:  I Faredin; I Tóth; J Oszlánczy; S Scultéty
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

4.  Unexpected virilization in male mice lacking steroid 5 alpha-reductase enzymes.

Authors:  M S Mahendroo; K M Cala; D L Hess; D W Russell
Journal:  Endocrinology       Date:  2001-11       Impact factor: 4.736

5.  Feed-forward control of prostate growth: dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5 alpha-reductase.

Authors:  F W George; D W Russell; J D Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

6.  Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a new type of specific competitive inhibitor of testosterone 5 alpha-reductase, in volunteers.

Authors:  M Ohtawa; H Morikawa; J Shimazaki
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

7.  5α-Reductase Isozymes in the Prostate.

Authors:  Yuan-Shan Zhu; Guang-Huan Sun
Journal:  J Med Sci       Date:  2005

8.  The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases.

Authors:  Faris Azzouni; Alejandro Godoy; Yun Li; James Mohler
Journal:  Adv Urol       Date:  2011-12-25

Review 9.  Role of 5 alpha-reductase inhibitors in the management of prostate cancer.

Authors:  Steven J Hudak; Javier Hernandez; Ian M Thompson
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.